Bowden NA - Search Results

1

Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma.

van der Westhuizen A, Knoblauch N, Graves MC, Levy R, Vilain RE, Bowden NA. van der Westhuizen A, et al. Among authors: bowden na. Medicine (Baltimore). 2020 Jun 19;99(25):e20705. doi: 10.1097/MD.0000000000020705. Medicine (Baltimore). 2020. PMID: 32569203 Free PMC article.

2

Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.

Bowden NA, Ashton KA, Vilain RE, Avery-Kiejda KA, Davey RJ, Murray HC, Budden T, Braye SG, Zhang XD, Hersey P, Scott RJ. Bowden NA, et al. PLoS One. 2013 Aug 5;8(8):e70424. doi: 10.1371/journal.pone.0070424. Print 2013. PLoS One. 2013. PMID: 23940574 Free PMC article.

3

Metastatic melanoma treatment: Combining old and new therapies.

Davey RJ, van der Westhuizen A, Bowden NA. Davey RJ, et al. Among authors: bowden na. Crit Rev Oncol Hematol. 2016 Feb;98:242-53. doi: 10.1016/j.critrevonc.2015.11.011. Epub 2015 Nov 17. Crit Rev Oncol Hematol. 2016. PMID: 26616525 Review.

4

Repair of UVB-induced DNA damage is reduced in melanoma due to low XPC and global genome repair.

Budden T, Davey RJ, Vilain RE, Ashton KA, Braye SG, Beveridge NJ, Bowden NA. Budden T, et al. Among authors: bowden na. Oncotarget. 2016 Sep 20;7(38):60940-60953. doi: 10.18632/oncotarget.10902. Oncotarget. 2016. PMID: 27487145 Free PMC article.

5

Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.

Budden T, van der Westhuizen A, Bowden NA. Budden T, et al. Among authors: bowden na. BMC Cancer. 2018 Jan 26;18(1):100. doi: 10.1186/s12885-018-4010-9. BMC Cancer. 2018. PMID: 29373959 Free PMC article.

6

Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer.

Scurry J, van Zyl B, Gulliver D, Otton G, Jaaback K, Lombard J, Vilain RE, Bowden NA. Scurry J, et al. Among authors: bowden na. Gynecol Oncol. 2018 Nov;151(2):306-310. doi: 10.1016/j.ygyno.2018.08.030. Epub 2018 Sep 5. Gynecol Oncol. 2018. PMID: 30194007

7

Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles.

Graves M, CelliMarchett G, van Zyl B, Tang D, Vilain RE, van der Westhuizen A, Bowden NA. Graves M, et al. Among authors: bowden na. Front Med (Lausanne). 2019 May 22;6:113. doi: 10.3389/fmed.2019.00113. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31192212 Free PMC article.

8

Targeting DNA Repair in Ovarian Cancer Treatment Resistance.

Wong-Brown MW, van der Westhuizen A, Bowden NA. Wong-Brown MW, et al. Among authors: bowden na. Clin Oncol (R Coll Radiol). 2020 Aug;32(8):518-526. doi: 10.1016/j.clon.2020.03.005. Epub 2020 Apr 3. Clin Oncol (R Coll Radiol). 2020. PMID: 32253106 Review.

9

Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response.

Navani V, Graves MC, Bowden NA, Van Der Westhuizen A. Navani V, et al. Among authors: bowden na. Br J Clin Pharmacol. 2020 Sep;86(9):1736-1752. doi: 10.1111/bcp.14352. Epub 2020 Jun 5. Br J Clin Pharmacol. 2020. PMID: 32384184 Free PMC article. Review.

10

DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets.

Lozinski M, Bowden NA, Graves MC, Fay M, Tooney PA. Lozinski M, et al. Among authors: bowden na. Cell Oncol (Dordr). 2021 Oct;44(5):961-981. doi: 10.1007/s13402-021-00613-0. Epub 2021 May 31. Cell Oncol (Dordr). 2021. PMID: 34057732 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

68 results

Search Page

Filters